Caplin Point Laboratories Limited

BSE: 524742 NSE: CAPLIPOINT
Caplin Point Laboratories Limited - pharma in Chennai, Tamil Nadu, India. FY 2026 financials and compliance.
CIN L24231TN1990PLC019053 Incorporated 16 April 1990 ROC Chennai HQ Chennai, Tamil Nadu, India
Active Listed - NSE: CAPLIPOINT · BSE: 524742 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹2,187.19 Cr
▲ 12.89% YoY
EBITDA · FY 2026
₹876.39 Cr
▲ 17.9% YoY
Net profit · FY 2026
₹649.73 Cr
▲ 20.08% YoY
Authorised capital
₹17 Cr
Registered with MCA
Paid-up capital
₹15.2 Cr
Issued & subscribed
Open charges
₹10 Lakh
Satisfied ₹102.92 Cr
Company age
36 yrs
Est. 1990
Employees · EPFO
987
Latest available

About Caplin Point Laboratories Limited

Data last updated: 05 January 2026

Caplin Point Laboratories Limited is a public limited company based in Chennai, Tamil Nadu, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 April 1990, the company has been in operation for over 36 years.

Registered with ROC Chennai under CIN L24231TN1990PLC019053. Listed on BSE: 524742 and NSE: CAPLIPOINT.

Capital: an authorised share capital of ₹17 Cr and a paid-up capital of ₹15.2 Cr. Formerly known as Caplin Point Laboratories Private Limited. It is led by directors including Komattu Chacko John and Desikachari Muralidharan.

Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Chennai, Tamil Nadu.

As per the financials filed for FY 2025, the company reported a revenue of ₹2,033.9 Cr, a growth of 15% compared to the previous year.

The company has a workforce of approximately 987 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 2 brands - Amaris Clinical, Caplin Point Laboratories. As per MCA filings, the company has open charges of ₹10 Lakh and satisfied charges of ₹102.92 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website caplinpoint.net.

Company Details of Caplin Point Laboratories Limited
CIN L24231TN1990PLC019053
Registration Number 019053
Incorporation Date 16 April 1990
ROC Chennai
Listing Status Listed (BSE: 524742, NSE: CAPLIPOINT)
Company Status Active
Date of Last AGM 22 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Desikachari Muralidharan Cfo Komattu Chacko John Additional Director Ramachandramurthy Nagendran Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    caplinpoint.net
  • Social Media
  • Registered Address
    Ashvich Towers 3Rd Floor No.3 Developed Plots Industrial Estates Per, Ungudi, Chennai, Tamil Nadu, India – 600096
  • Industry
    Pharma, Drug Formulation & Development
Company report
Caplin Point Laboratories Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Caplin Point Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Caplin Point Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has one previous CIN (Corporate Identification Number): L24231TN1990PTC019053. The current CIN is L24231TN1990PLC019053, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24231TN1990PLC019053 Current
L24231TN1990PTC019053 Previous

Associated Brands with Caplin Point Laboratories Limited

Caplin Point Laboratories Limited operates two associated brands: Amaris Clinical and Caplin Point laboratories. These brands represent Caplin Point Laboratories Limited's diversified market presence and brand portfolio.

Brand Description Website
Caplin Point laboratories
Manufacturer of a pharmaceutical generics and biotech products caplinpoint.net
Amaris Clinical
Clinical research, bioanalysis, and technical services are offered by Amaris Clinical. amarisclinical.com

Business Activity of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is audited by Brahmayya & Co. (ICAI peer reviewed, certificate valid till 2027-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Brahmayya & Co. (ICAI peer reviewed, certificate valid till 2027-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is currently managed by 12 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Komattu Chacko John
Also directs: Caplin Steriles Limited
Additional Director 05 Nov 2025 0 Years 8 Months Current
Desikachari Muralidharan Cfo 19 Feb 2016 10 Years 4 Months Current
Ramachandramurthy Nagendran
Also directs: Sriman Madhwa Sidhantaonnahini Permanent Nidhi Limited
Director 29 Sep 2022 3 Years 9 Months Current
Sridhar Ganesan
Also directs: Caplin Steriles Limited, Argus Salud Pharma Llp, Caplin One Labs Limited
Deputy Nodal Officer 25 Jul 2022 3 Years 11 Months Current
Partheeban Vivek Siddarth
Also directs: Caplin Steriles Limited, May India Property Private Limited, Ashvich Infotek Private Limited and 3 more
Additional Director 05 Nov 2025 0 Years 8 Months Current
Ranganathan Vijayaraghavan
Also directs: The United Nilgiri Tea Estates Company Limited, Sundram Fasteners Limited, Lucas Indian Service Limited and 2 more
Director 30 Sep 2024 1 Years 9 Months Current
Showing 6 of 12 current directors. View all directors

Financials of Caplin Point Laboratories Limited FY 2026 filings available

Caplin Point Laboratories Limited reported revenue of ₹2,187.19 Cr (up 12.89% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹2,187.19 Cr ▲ 12.89%
Profit · FY 2026
₹649.73 Cr ▲ 20.08%
EBITDA · FY 2026
₹876.39 Cr ▲ 17.9%
Revenue₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹863 Cr863FY 2020FY 2021: ₹1,061 Cr · +22.9% YoY1,061+22.9%FY 2021FY 2022: ₹1,269 Cr · +19.6% YoY1,269+19.6%FY 2022FY 2023: ₹1,467 Cr · +15.5% YoY1,467+15.5%FY 2023FY 2024: ₹1,694 Cr · +15.5% YoY1,694+15.5%FY 2024FY 2025: ₹1,937 Cr · +14.4% YoY1,937+14.4%FY 2025FY 2026: ₹2,187 Cr · +12.9% YoY2,187+12.9%FY 2026
Net Profit₹ Cr · Consolidated0250500750FY 2020: ₹215 Cr215FY 2020FY 2021: ₹251 Cr · +16.9% YoY251+16.9%FY 2021FY 2022: ₹308 Cr · +22.7% YoY308+22.7%FY 2022FY 2023: ₹377 Cr · +22.2% YoY377+22.2%FY 2023FY 2024: ₹461 Cr · +22.4% YoY461+22.4%FY 2024FY 2025: ₹541 Cr · +17.3% YoY541+17.3%FY 2025FY 2026: ₹650 Cr · +20.1% YoY650+20.1%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0250500750Q1'25: ₹459 Cr · +16.1% YoY459+16.1%Q1'25Q2'25: ₹483 Cr · +17.8% YoY483+17.8%Q2'25Q3'25: ₹493 Cr · +13.2% YoY493+13.2%Q3'25Q4'25: ₹502 Cr · +10.9% YoY502+10.9%Q4'25Q1'26: ₹510 Cr · +11.2% YoY510+11.2%Q1'26Q2'26: ₹534 Cr · +10.5% YoY534+10.5%Q2'26Q3'26: ₹543 Cr · +10.1% YoY543+10.1%Q3'26Q4'26: ₹600 Cr · +19.4% YoY600+19.4%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,187.19 Cr ₹1,937.47 Cr ₹1,694.1 Cr ₹1,466.73 Cr ₹1,269.41 Cr ₹1,061.29 Cr ₹863.2 Cr
Other Income ₹115.54 Cr ₹96.43 Cr ₹66.94 Cr ₹55.98 Cr ₹38.75 Cr ₹23.54 Cr ₹41.33 Cr
Total Income ₹2,302.73 Cr ₹2,033.9 Cr ₹1,761.04 Cr ₹1,522.71 Cr ₹1,308.16 Cr ₹1,084.83 Cr ₹904.54 Cr
Cost of Materials Consumed ₹357.2 Cr ₹248.45 Cr ₹239.81 Cr ₹223.04 Cr ₹192.31 Cr ₹129.82 Cr ₹108.12 Cr
Purchases of Stock-in-Trade ₹572.2 Cr ₹575.7 Cr ₹558.92 Cr ₹519.03 Cr ₹397.13 Cr ₹259.57 Cr ₹500.14 Cr
Changes in Inventories -₹63.72 Cr -₹53.31 Cr -₹74.55 Cr -₹78.86 Cr -₹31.93 Cr ₹82.35 Cr -₹195.1 Cr
Employee Benefit Expense ₹199.15 Cr ₹177.72 Cr ₹143.59 Cr ₹136.99 Cr ₹115.3 Cr ₹102.53 Cr ₹67.76 Cr
Finance Costs ₹87 Lakh ₹61 Lakh ₹78 Lakh ₹78 Lakh ₹70 Lakh ₹1.59 Cr ₹31.97 Lakh
Depreciation & Amortisation ₹72.77 Cr ₹65.96 Cr ₹53.44 Cr ₹44.99 Cr ₹46.9 Cr ₹36.97 Cr ₹31.62 Cr
Other Expenses ₹361.51 Cr ₹341.98 Cr ₹274.89 Cr ₹225.47 Cr ₹201.93 Cr ₹158.38 Cr ₹122.21 Cr
Total Expenses ₹1,499.98 Cr ₹1,357.11 Cr ₹1,196.88 Cr ₹1,071.44 Cr ₹922.34 Cr ₹771.21 Cr ₹635.07 Cr
Profit Before Exceptional Items & Tax ₹802.75 Cr ₹676.79 Cr ₹564.16 Cr ₹451.27 Cr ₹385.82 Cr ₹313.62 Cr ₹269.46 Cr
Exceptional Items ₹4 Lakh ₹0 ₹27 Lakh ₹8 Lakh ₹0 ₹0 ₹0
Profit Before Tax ₹802.79 Cr ₹676.79 Cr ₹564.43 Cr ₹451.35 Cr ₹385.82 Cr ₹313.62 Cr ₹269.46 Cr
Total Tax Expense ₹153.06 Cr ₹135.69 Cr ₹103.01 Cr ₹74.36 Cr ₹77.37 Cr ₹62.18 Cr ₹54.38 Cr
Net Profit ₹649.73 Cr ₹541.09 Cr ₹461.42 Cr ₹376.99 Cr ₹308.45 Cr ₹251.44 Cr ₹215.08 Cr
  attributable to Owners ₹641.24 Cr ₹563.38 Cr ₹457.08 Cr ₹376.26 Cr - ₹242.28 Cr ₹215.01 Cr
  attributable to NCI ₹8.49 Cr ₹4.78 Cr ₹4.33 Cr ₹73 Lakh - ₹9.16 Cr ₹7.57 Lakh
Other Comprehensive Income ₹141.64 Cr ₹27.07 Cr ₹11.45 Cr ₹42.75 Cr ₹14.26 Cr -₹7.16 Cr ₹16.67 Cr
Total Comprehensive Income ₹791.37 Cr ₹568.16 Cr ₹472.87 Cr ₹419.74 Cr ₹322.71 Cr ₹244.28 Cr ₹231.75 Cr
EBITDA (computed) ₹876.39 Cr ₹743.36 Cr ₹618.38 Cr ₹497.04 Cr ₹433.42 Cr ₹352.18 Cr ₹301.4 Cr
Basic EPS ₹84.36 ₹70.57 ₹60.19 ₹49.62 ₹39.61 ₹32.03 ₹28.42
Diluted EPS ₹84.11 ₹70.25 ₹59.90 ₹49.18 ₹39.26 ₹31.71 ₹28.20
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹4,045.48 Cr ₹3,208.58 Cr ₹2,697.37 Cr ₹2,191.4 Cr
Non-current Assets ₹1,459.82 Cr ₹1,074.63 Cr ₹805.16 Cr ₹636.94 Cr
Current Assets ₹2,585.66 Cr ₹2,133.95 Cr ₹1,892.21 Cr ₹1,554.46 Cr
Property, Plant & Equipment ₹547.49 Cr ₹530.32 Cr ₹438.62 Cr ₹267.01 Cr
Inventories ₹428.86 Cr ₹336.1 Cr ₹363.04 Cr ₹288.22 Cr
Trade Receivables ₹825.81 Cr ₹632.49 Cr ₹542.72 Cr ₹394.06 Cr
Cash & Equivalents ₹94.18 Cr ₹199.45 Cr ₹138.7 Cr ₹177.56 Cr
Equity (Net Worth) ₹3,630.8 Cr ₹2,886.39 Cr ₹2,346.82 Cr ₹1,907.27 Cr
Equity Share Capital ₹15.2 Cr ₹15.2 Cr ₹15.19 Cr ₹15.18 Cr
Borrowings (Non-current) ₹0 ₹0 ₹92 Lakh ₹0
Borrowings (Current) ₹57 Lakh ₹55 Lakh ₹28 Lakh ₹3.41 Cr
Total Debt (computed) ₹57 Lakh ₹55 Lakh ₹1.2 Cr ₹3.41 Cr
Current Liabilities ₹385.94 Cr ₹306.38 Cr ₹330.55 Cr ₹268 Cr
Total Liabilities ₹414.68 Cr ₹322.19 Cr ₹350.55 Cr ₹284.13 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹523.23 Cr ₹432.37 Cr ₹310.98 Cr ₹271.65 Cr ₹336.75 Cr
Investing Cash Flow -₹582.29 Cr -₹334.73 Cr -₹312.63 Cr -₹217.86 Cr -₹270.94 Cr
Financing Cash Flow -₹46.46 Cr -₹38.32 Cr -₹38.07 Cr -₹28.17 Cr -₹40.71 Cr
Capital Expenditure ₹248.13 Cr ₹191.52 Cr ₹145.81 Cr ₹193.75 Cr ₹91.18 Cr
Free Cash Flow (computed) ₹275.1 Cr ₹240.85 Cr ₹165.17 Cr ₹77.9 Cr ₹245.57 Cr
Dividends Paid ₹45.61 Cr ₹37.99 Cr ₹34.17 Cr ₹30.32 Cr ₹22.69 Cr
Net Change in Cash -₹105.27 Cr ₹59.32 Cr -₹38.86 Cr ₹26.8 Cr ₹25.01 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹600.16 Cr ₹542.77 Cr ₹534.04 Cr ₹510.22 Cr ₹502.45 Cr ₹492.96 Cr ₹483.1 Cr ₹458.96 Cr ₹453.22 Cr ₹435.5 Cr ₹410.06 Cr ₹395.32 Cr
Other Income ₹28.36 Cr ₹33.68 Cr ₹30.37 Cr ₹23.14 Cr ₹25.74 Cr ₹31.36 Cr ₹20.77 Cr ₹18.56 Cr ₹17.29 Cr ₹17.18 Cr ₹20.43 Cr ₹12.04 Cr
Total Income ₹628.52 Cr ₹576.45 Cr ₹564.41 Cr ₹533.36 Cr ₹528.19 Cr ₹524.32 Cr ₹503.87 Cr ₹477.52 Cr ₹470.51 Cr ₹452.68 Cr ₹430.49 Cr ₹407.36 Cr
Cost of Materials Consumed ₹102.11 Cr ₹89.24 Cr ₹92.34 Cr ₹73.51 Cr ₹60.84 Cr ₹59.8 Cr ₹69.23 Cr ₹63.65 Cr ₹57.87 Cr ₹50.96 Cr ₹66.85 Cr ₹64.14 Cr
Purchases of Stock-in-Trade ₹209.02 Cr ₹128 Cr ₹121.68 Cr ₹113.5 Cr ₹138.77 Cr ₹139.43 Cr ₹122.33 Cr ₹74.48 Cr ₹121.78 Cr ₹179.77 Cr ₹129.33 Cr ₹128.04 Cr
Changes in Inventories -₹66.13 Cr -₹2.1 Cr -₹3.72 Cr ₹8.23 Cr ₹1.59 Cr -₹3.88 Cr -₹2.74 Cr ₹47.35 Cr ₹11.72 Cr -₹40.61 Cr -₹32.08 Cr -₹13.58 Cr
Employee Benefit Expense ₹52.62 Cr ₹49.78 Cr ₹47.23 Cr ₹43.16 Cr ₹46.51 Cr ₹46.77 Cr ₹44.29 Cr ₹40.15 Cr ₹36.77 Cr ₹36.67 Cr ₹35.08 Cr ₹35.07 Cr
Finance Costs ₹36 Lakh ₹18 Lakh ₹16 Lakh ₹18 Lakh ₹17 Lakh ₹18 Lakh ₹21 Lakh ₹5 Lakh ₹15 Lakh ₹17 Lakh ₹17.8 Lakh ₹28 Lakh
Depreciation & Amortisation ₹18.8 Cr ₹19.28 Cr ₹18.4 Cr ₹16.29 Cr ₹17.04 Cr ₹16.2 Cr ₹16.76 Cr ₹15.96 Cr ₹16.4 Cr ₹13.9 Cr ₹11.77 Cr ₹11.38 Cr
Other Expenses ₹98.3 Cr ₹88.16 Cr ₹87.34 Cr ₹94.06 Cr ₹86.68 Cr ₹88.55 Cr ₹85.23 Cr ₹81.52 Cr ₹79.85 Cr ₹66.44 Cr ₹73.48 Cr ₹55.04 Cr
Total Expenses ₹415.08 Cr ₹372.54 Cr ₹363.43 Cr ₹348.93 Cr ₹351.6 Cr ₹347.05 Cr ₹335.31 Cr ₹323.16 Cr ₹324.54 Cr ₹307.3 Cr ₹284.6 Cr ₹280.37 Cr
Profit Before Exceptional Items & Tax ₹213.44 Cr ₹203.91 Cr ₹200.98 Cr ₹184.43 Cr ₹176.59 Cr ₹177.27 Cr ₹168.56 Cr ₹154.36 Cr ₹145.97 Cr ₹145.38 Cr ₹145.89 Cr ₹126.99 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6 Lakh ₹0 ₹0 ₹0
Profit Before Tax ₹213.44 Cr ₹203.91 Cr ₹200.98 Cr ₹184.43 Cr ₹176.59 Cr ₹177.27 Cr ₹168.56 Cr ₹154.36 Cr ₹146.03 Cr ₹145.38 Cr ₹145.89 Cr ₹126.99 Cr
Total Tax Expense ₹40.56 Cr ₹38.03 Cr ₹40.77 Cr ₹33.7 Cr ₹31.39 Cr ₹37.19 Cr ₹37.65 Cr ₹29.46 Cr ₹24.8 Cr ₹25.58 Cr ₹29.86 Cr ₹22.76 Cr
Net Profit ₹172.88 Cr ₹165.86 Cr ₹160.23 Cr ₹150.76 Cr ₹145.28 Cr ₹140.07 Cr ₹130.81 Cr ₹124.92 Cr ₹121.23 Cr ₹119.83 Cr ₹116.15 Cr ₹104.23 Cr
  attributable to Owners ₹170.11 Cr ₹163.88 Cr ₹154.45 Cr ₹152.8 Cr ₹140.82 Cr ₹138.96 Cr ₹130.8 Cr ₹123.97 Cr ₹121.59 Cr ₹117.2 Cr ₹114.87 Cr ₹103.43 Cr
  attributable to NCI ₹2.77 Cr ₹1.98 Cr ₹5.78 Cr -₹2.04 Cr ₹2.71 Cr ₹1.11 Cr ₹1 Lakh ₹95 Lakh -₹36 Lakh ₹2.62 Cr ₹1.27 Cr ₹80 Lakh
Other Comprehensive Income ₹76.9 Cr ₹16.84 Cr ₹47.54 Cr ₹36 Lakh -₹1.75 Cr ₹22.81 Cr ₹1.33 Cr ₹4.68 Cr ₹3.26 Cr ₹86.6 Lakh ₹9.67 Cr -₹2.33 Cr
Total Comprehensive Income ₹249.78 Cr ₹182.7 Cr ₹207.77 Cr ₹151.12 Cr ₹143.53 Cr ₹162.88 Cr ₹132.14 Cr ₹129.6 Cr ₹124.49 Cr ₹120.69 Cr ₹125.81 Cr ₹101.9 Cr
EBITDA (computed) ₹232.6 Cr ₹223.37 Cr ₹219.54 Cr ₹200.9 Cr ₹193.8 Cr ₹193.65 Cr ₹185.53 Cr ₹170.37 Cr ₹162.52 Cr ₹159.45 Cr ₹157.83 Cr ₹138.65 Cr
Basic EPS ₹22.38 ₹21.56 ₹20.32 ₹20.10 ₹18.75 ₹18.28 ₹17.22 ₹16.32 ₹16.01 ₹15.44 ₹15.13 ₹13.62
Diluted EPS ₹22.31 ₹21.51 ₹20.25 ₹20.03 ₹18.69 ₹18.19 ₹17.12 ₹16.24 ₹15.90 ₹15.39 ₹15.06 ₹13.55
Latest 12 quarters shown of 25 on record.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Rest of the World ₹470.25 Cr ₹163.32 Cr ₹1,918.28 Cr ₹332.52 Cr
USA ₹129.91 Cr ₹21.76 Cr ₹656 Cr ₹82.16 Cr
Unallocated ₹28.36 Cr ₹28.36 Cr ₹1,471.2 Cr ₹0
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Rest of the World ₹1,733.79 Cr ₹631.2 Cr - -
USA ₹453.4 Cr ₹56.05 Cr - -
Unallocated ₹115.54 Cr ₹115.54 Cr - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹738.33 Cr ₹752.41 Cr ₹625.09 Cr ₹528.61 Cr ₹528.06 Cr ₹482.68 Cr ₹527.83 Cr
Other Income ₹195.37 Cr ₹134.59 Cr ₹105.84 Cr ₹99 Cr ₹56.55 Cr ₹18.62 Cr ₹65.97 Cr
Total Income ₹933.7 Cr ₹887 Cr ₹730.93 Cr ₹627.61 Cr ₹584.61 Cr ₹501.3 Cr ₹593.8 Cr
Cost of Materials Consumed ₹158.82 Cr ₹136.64 Cr ₹172.13 Cr ₹151.35 Cr ₹156.01 Cr ₹112.48 Cr ₹95.73 Cr
Purchases of Stock-in-Trade ₹82.51 Cr ₹77.17 Cr ₹76.77 Cr ₹48.38 Cr ₹57.64 Cr ₹82.92 Cr ₹143.18 Cr
Changes in Inventories -₹12.37 Cr ₹24.36 Cr -₹43.68 Cr -₹1.67 Cr -₹9 Cr -₹57 Lakh -₹74.1 Lakh
Employee Benefit Expense ₹47.72 Cr ₹52.13 Cr ₹38.11 Cr ₹36.68 Cr ₹30.47 Cr ₹26.59 Cr ₹25 Cr
Finance Costs ₹20 Lakh ₹12 Lakh ₹10 Lakh ₹12 Lakh ₹9 Lakh ₹17 Lakh ₹18.5 Lakh
Depreciation & Amortisation ₹25.43 Cr ₹24.77 Cr ₹27.08 Cr ₹25.65 Cr ₹25.77 Cr ₹22.44 Cr ₹19.65 Cr
Other Expenses ₹123.87 Cr ₹130.14 Cr ₹94.68 Cr ₹73.95 Cr ₹73.32 Cr ₹47.33 Cr ₹57.66 Cr
Total Expenses ₹426.18 Cr ₹445.33 Cr ₹365.19 Cr ₹334.46 Cr ₹334.3 Cr ₹291.36 Cr ₹340.67 Cr
Profit Before Exceptional Items & Tax ₹507.52 Cr ₹441.67 Cr ₹365.74 Cr ₹293.15 Cr ₹250.31 Cr ₹209.94 Cr ₹253.12 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹507.52 Cr ₹441.67 Cr ₹365.74 Cr ₹293.15 Cr ₹250.31 Cr ₹209.94 Cr ₹253.12 Cr
Total Tax Expense ₹110.94 Cr ₹102.18 Cr ₹82.03 Cr ₹58.89 Cr ₹62.44 Cr ₹53.71 Cr ₹55.49 Cr
Net Profit ₹396.58 Cr ₹339.49 Cr ₹283.71 Cr ₹234.26 Cr ₹187.87 Cr ₹156.23 Cr ₹197.64 Cr
  attributable to Owners - - - - - - ₹0
  attributable to NCI - - - - - - ₹0
Other Comprehensive Income -₹7 Lakh -₹10 Lakh -₹16 Lakh ₹11 Lakh ₹10 Lakh ₹22 Lakh -₹33.47 Lakh
Total Comprehensive Income ₹396.51 Cr ₹339.39 Cr ₹283.55 Cr ₹234.37 Cr ₹187.97 Cr ₹156.45 Cr ₹197.3 Cr
EBITDA (computed) ₹533.15 Cr ₹466.56 Cr ₹392.92 Cr ₹318.92 Cr ₹276.17 Cr ₹232.55 Cr ₹272.96 Cr
Basic EPS ₹52.17 ₹44.67 ₹37.36 ₹30.89 ₹24.82 ₹20.65 ₹26.13
Diluted EPS ₹52.02 ₹44.47 ₹37.18 ₹30.62 ₹24.60 ₹20.45 ₹25.95
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,211.74 Cr ₹1,814.48 Cr ₹1,522.31 Cr ₹1,303.18 Cr
Non-current Assets ₹1,235.86 Cr ₹988.79 Cr ₹819.81 Cr ₹639.2 Cr
Current Assets ₹975.88 Cr ₹825.69 Cr ₹702.5 Cr ₹663.98 Cr
Property, Plant & Equipment ₹219.68 Cr ₹201.59 Cr ₹161.77 Cr ₹151.7 Cr
Inventories ₹85.66 Cr ₹66.26 Cr ₹86.25 Cr ₹51.53 Cr
Trade Receivables ₹265.96 Cr ₹175.33 Cr ₹128.67 Cr ₹88.24 Cr
Cash & Equivalents ₹44.09 Cr ₹99.64 Cr ₹80.64 Cr ₹122.02 Cr
Equity (Net Worth) ₹2,050.5 Cr ₹1,700.93 Cr ₹1,390.15 Cr ₹1,139.91 Cr
Equity Share Capital ₹15.2 Cr ₹15.2 Cr ₹15.19 Cr ₹15.18 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹144.17 Cr ₹99.85 Cr ₹119.3 Cr ₹146.85 Cr
Total Liabilities ₹161.24 Cr ₹113.55 Cr ₹132.16 Cr ₹163.27 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹214.78 Cr ₹195.87 Cr ₹104.21 Cr ₹157.1 Cr ₹230.97 Cr
Investing Cash Flow -₹224.77 Cr -₹140.2 Cr -₹112.14 Cr -₹86.67 Cr -₹237.18 Cr
Financing Cash Flow -₹45.81 Cr -₹38.1 Cr -₹34.26 Cr -₹30.42 Cr -₹22.76 Cr
Capital Expenditure ₹44.63 Cr ₹56.56 Cr ₹23.07 Cr ₹58.63 Cr ₹7.22 Cr
Free Cash Flow (computed) ₹170.15 Cr ₹139.31 Cr ₹81.14 Cr ₹98.47 Cr ₹223.75 Cr
Dividends Paid ₹0 ₹37.99 Cr ₹34.17 Cr ₹30.32 Cr ₹22.69 Cr
Net Change in Cash -₹55.55 Cr ₹17.57 Cr -₹41.38 Cr ₹41.01 Cr -₹29.06 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹191.36 Cr ₹189.22 Cr ₹175.18 Cr ₹182.57 Cr ₹173.61 Cr ₹185.23 Cr ₹207.93 Cr ₹185.64 Cr ₹139.38 Cr ₹132.83 Cr ₹179.22 Cr ₹173.66 Cr
Other Income ₹61.08 Cr ₹31.73 Cr ₹59.22 Cr ₹32.03 Cr ₹41.25 Cr ₹28.83 Cr ₹43.01 Cr ₹21.5 Cr ₹36.18 Cr ₹17.9 Cr ₹24.49 Cr ₹27.27 Cr
Total Income ₹252.44 Cr ₹220.95 Cr ₹234.4 Cr ₹214.6 Cr ₹214.86 Cr ₹214.06 Cr ₹250.94 Cr ₹207.14 Cr ₹175.56 Cr ₹150.73 Cr ₹203.71 Cr ₹200.93 Cr
Cost of Materials Consumed ₹45.8 Cr ₹39.47 Cr ₹34.92 Cr ₹38.62 Cr ₹34.25 Cr ₹33.29 Cr ₹32.72 Cr ₹36.38 Cr ₹40.18 Cr ₹43.43 Cr ₹45.84 Cr ₹42.68 Cr
Purchases of Stock-in-Trade ₹24.67 Cr ₹23.45 Cr ₹21.21 Cr ₹13.18 Cr ₹17.39 Cr ₹19.24 Cr ₹24.36 Cr ₹16.18 Cr ₹22.91 Cr ₹13.05 Cr ₹19.97 Cr ₹20.84 Cr
Changes in Inventories -₹14.89 Cr -₹5.8 Cr ₹2.05 Cr ₹6.27 Cr ₹3.66 Cr ₹8.19 Cr ₹4.7 Cr ₹7.81 Cr -₹19.59 Cr -₹14.93 Cr -₹9.37 Cr ₹21 Lakh
Employee Benefit Expense ₹13.15 Cr ₹13.41 Cr ₹11.54 Cr ₹9.63 Cr ₹14.39 Cr ₹13.89 Cr ₹12.99 Cr ₹10.86 Cr ₹9.77 Cr ₹9.52 Cr ₹9.1 Cr ₹9.72 Cr
Finance Costs ₹5 Lakh ₹7 Lakh ₹5 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹2 Lakh ₹2 Lakh ₹2 Lakh ₹3 Lakh ₹2.1 Lakh ₹3 Lakh
Depreciation & Amortisation ₹6.9 Cr ₹6.37 Cr ₹6.02 Cr ₹6.14 Cr ₹6.09 Cr ₹6.01 Cr ₹6.49 Cr ₹6.18 Cr ₹6.93 Cr ₹6.76 Cr ₹6.72 Cr ₹6.67 Cr
Other Expenses ₹39.04 Cr ₹26.97 Cr ₹29.61 Cr ₹28.26 Cr ₹28.88 Cr ₹33.23 Cr ₹35 Cr ₹33.03 Cr ₹28.43 Cr ₹18.44 Cr ₹24.23 Cr ₹23.59 Cr
Total Expenses ₹114.72 Cr ₹103.94 Cr ₹105.4 Cr ₹102.14 Cr ₹104.7 Cr ₹113.89 Cr ₹116.28 Cr ₹110.46 Cr ₹88.65 Cr ₹76.29 Cr ₹96.51 Cr ₹103.74 Cr
Profit Before Exceptional Items & Tax ₹137.72 Cr ₹117.01 Cr ₹129 Cr ₹112.46 Cr ₹110.16 Cr ₹100.17 Cr ₹134.66 Cr ₹96.68 Cr ₹86.91 Cr ₹74.43 Cr ₹107.2 Cr ₹97.19 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹137.72 Cr ₹117.01 Cr ₹129 Cr ₹112.46 Cr ₹110.16 Cr ₹100.17 Cr ₹134.66 Cr ₹96.68 Cr ₹86.91 Cr ₹74.43 Cr ₹107.2 Cr ₹97.19 Cr
Total Tax Expense ₹28.22 Cr ₹29.73 Cr ₹26.41 Cr ₹26.57 Cr ₹23.66 Cr ₹25.46 Cr ₹28.92 Cr ₹24.14 Cr ₹17.03 Cr ₹18.98 Cr ₹25.1 Cr ₹20.92 Cr
Net Profit ₹109.5 Cr ₹87.28 Cr ₹102.59 Cr ₹85.89 Cr ₹86.5 Cr ₹74.71 Cr ₹105.74 Cr ₹72.54 Cr ₹69.88 Cr ₹55.45 Cr ₹82.1 Cr ₹76.27 Cr
Other Comprehensive Income -₹13 Lakh -₹44 Lakh ₹50 Lakh ₹0 -₹22 Lakh ₹0 ₹12 Lakh ₹0 -₹28 Lakh ₹0 ₹14 Lakh ₹0
Total Comprehensive Income ₹109.37 Cr ₹86.84 Cr ₹103.09 Cr ₹85.89 Cr ₹86.28 Cr ₹74.71 Cr ₹105.86 Cr ₹72.54 Cr ₹69.6 Cr ₹55.45 Cr ₹82.24 Cr ₹76.27 Cr
EBITDA (computed) ₹144.67 Cr ₹123.45 Cr ₹135.07 Cr ₹118.64 Cr ₹116.29 Cr ₹106.22 Cr ₹141.17 Cr ₹102.88 Cr ₹93.86 Cr ₹81.22 Cr ₹113.94 Cr ₹103.89 Cr
Basic EPS ₹15.89 ₹11.49 ₹13.50 ₹11.30 ₹11.37 ₹9.83 ₹13.92 ₹9.55 ₹9.20 ₹7.30 ₹10.82 ₹10.04
Diluted EPS ₹15.85 ₹11.46 ₹13.45 ₹11.26 ₹11.35 ₹9.77 ₹13.85 ₹9.50 ₹9.14 ₹7.29 ₹10.76 ₹9.99
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Caplin Point Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Caplin Point Laboratories Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 70.57%, foreign institutional investors hold 6.15%, domestic institutional investors hold 2.14%, retail and other public shareholders hold 21.14% of Caplin Point Laboratories Limited. The company had 93,896 shareholders on record.

Promoters: 70.57%DII (Domestic Institutional): 2.14%FII (Foreign Institutional): 6.15%Retail & Others: 21.14%
Mar 2026
QUARTER
70.57% Promoters
2.14% DII (Domestic Institutional)
6.15% FII (Foreign Institutional)
21.14% Retail & Others
Promoter holding - history
Now 70.57% · Mar 2026High 70.66% · Mar 2023Low 67.81% · Dec 2015
66%67.5%69%70.5%72%Dec 2015Mar 2018Sep 2020Mar 2023Sep 2025Dec 2015: 67.81%Mar 2016: 67.81%Jun 2016: 69.09%Sep 2016: 69.09%Oct 2016: 69.09%Dec 2016: 69.09%Mar 2017: 69.06%Jun 2017: 69.06%Sep 2017: 69.06%Dec 2017: 69.06%Mar 2018: 69.04%Jun 2018: 69.05%Sep 2018: 69.05%Dec 2018: 69.05%Mar 2019: 69.04%Jun 2019: 69.03%Sep 2019: 69.03%Dec 2019: 69.03%Mar 2020: 69.03%Jun 2020: 69.03%Sep 2020: 69.03%Dec 2020: 69.03%Mar 2021: 69.03%Jun 2021: 69.03%Sep 2021: 69.03%Dec 2021: 68.91%Mar 2022: 68.89%Jun 2022: 68.88%Sep 2022: 68.88%Dec 2022: 68.80%Mar 2023: 70.66%Jun 2023: 70.63%Sep 2023: 70.63%Dec 2023: 70.62%Mar 2024: 70.62%Jun 2024: 70.56%Sep 2024: 70.56%Dec 2024: 70.56%Mar 2025: 70.56%Jun 2025: 70.56%Sep 2025: 70.57%Dec 2025: 70.57%Mar 2026: 70.57%70.66%67.81%70.57%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters70.57%70.57%70.57%70.56%70.56%70.56%
Public29.43%29.43%29.43%29.44%29.44%29.44%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters70.57%70.56%70.62%70.66%68.89%69.03%69.03%69.04%69.04%69.06%67.81%
Public29.43%29.44%29.38%29.34%31.11%30.97%30.96%30.96%30.96%30.94%32.19%
Promoter change (YoY, %pts)+0.01-0.06-0.04+1.77-0.14+0.00-0.01+0.00-0.02+1.25-

Board & Governance of Caplin Point Laboratories Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Caplin Point Laboratories Limited has 10 directors - 6 independent and 1 executive. The board is chaired by C C Paarthipan.

DirectorPositionOn board sinceListed boards
C C Paarthipan Non-Executive - Non Independent Director · Chairperson 1993-10-01 1
Sridhar Ganesan Executive Director · MD 2014-02-12 1
C K Gariyali Non-Executive - Independent Director 2020-03-04 1
R Nagendran Non-Executive - Independent Director 2022-09-29 1
S Deenadayalan Non-Executive - Independent Director 2022-09-29 1
Ranganathan Vijayaraghavan Non-Executive - Independent Director 2024-09-30 3
Ashok Partheeban Non-Executive - Non Independent Director 2025-11-05 1
K C John Non-Executive - Independent Director 2025-11-05 1
Vivek Partheeban Non-Executive - Non Independent Director 2025-11-05 1
Susan Mathew Non-Executive - Independent Director 2026-01-31 1
Board Committees
CommitteeMembers
Audit Committee Ranganathan Vijayaraghavan (Chairperson), R Nagendran, Sridhar Ganesan, S Deenadayalan
Nomination and remuneration committee S Deenadayalan (Chairperson), C K Gariyali, C C Paarthipan, K C John
Stakeholders Relationship Committee S Deenadayalan (Chairperson), Ranganathan Vijayaraghavan, Sridhar Ganesan
Risk Management Committee S Deenadayalan (Chairperson), Sridhar Ganesan, D Muralidharan, Vivek Partheeban, K C John
Corporate Social Responsibility Committee C C Paarthipan (Chairperson), S Deenadayalan, Sridhar Ganesan

Group Structure of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Caplin Point Laboratories Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
1
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Caplin One Labs Limited U24299TN2021PLC143869 -
Caplin Steriles Limited U24304TN2018PLC126270 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Caplin Point Laboratories Limited

Open charges
₹10 Lakh
Satisfied charges
₹102.92 Cr
Breakdown by lending institutions
Indian Overseas Bank₹0.10 Cr
Latest charge details
DateLenderAmountStatus
21 Jan 1994 Indian Overseas Bank ₹10 Lakh Open
02 May 2024 Others ₹7.6 Cr Satisfied
28 Apr 2023 Others ₹10 Cr Satisfied
30 Nov 2021 Others ₹7.6 Cr Satisfied
23 Mar 2016 Others ₹80 Lakh Satisfied

Total charge records: 18 View all charges

Employees and EPFO Compliance at Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has a workforce of 987 employees as of Mar 29, 2025.

Employee count
987
Active EPFO establishments
1
Employee growth
12.93%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Caplin Point Laboratories Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Caplin Point Laboratories Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Caplin Point Laboratories Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Caplin Point Laboratories Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Caplin Point Laboratories Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Caplin Point Laboratories Limited

MSME Payment Delays by Caplin Point Laboratories Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Caplin Point Laboratories Limited

Subsidiaries & Group Companies of Caplin Point Laboratories Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Caplin Point Laboratories Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Caplin Point Laboratories Limited

MCA Filings & Documents of Caplin Point Laboratories Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Caplin Point Laboratories Limited

Directors
05 Nov 2025
Komattu Chacko John was appointed as a Additional Director on 05 Nov 2025 & has been associated with this company since 8 months 3 days.
Directors
05 Nov 2025
Partheeban Vivek Siddarth was appointed as a Additional Director on 05 Nov 2025 & has been associated with this company since 8 months 3 days.
Directors
05 Nov 2025
Ashok Gorkey Partheeban was appointed as a Additional Director on 05 Nov 2025 & has been associated with this company since 8 months 3 days.
Activity
22 Sep 2025
Caplin Point Laboratories Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Charges
31 Jul 2025
A charge registered on 07 May 2007 via Charge ID 10052661 with The Catholic Syrian Bank Ltd was fully satisfied on 31 Jul 2025.
Charges
04 Jun 2025
A charge registered on 28 Apr 2023 via Charge ID 100721464 with Others was fully satisfied on 04 Jun 2025.

Recent News on Caplin Point Laboratories Limited

Frequently Asked Questions about Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is an active public limited company in the pharma sector based in Chennai, Tamil Nadu, India. It was incorporated on 16 April 1990 (36+ years old) and is registered under CIN L24231TN1990PLC019053. Listed on BSE: 524742 and NSE: CAPLIPOINT. The company has 987 employees.

Caplin Point Laboratories Limited reported revenue of ₹2,033.9 Cr for FY 2025 (up 15.00% YoY).

The current directors of Caplin Point Laboratories Limited are:

The primary industry of Caplin Point Laboratories Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Caplin Point Laboratories Limited is listed on both BSE (code: 524742) and NSE (symbol: CAPLIPOINT).

Caplin Point Laboratories Limited can be reached at the registered office: Ashvich Towers 3Rd Floor No.3 Developed Plots Industrial Estates Per, Ungudi, Chennai, Tamil Nadu, India – 600096, or through the website caplinpoint.net.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available